GENinCode

25/04/2024

World DNA Day is an annual, global celebration of the discovery of the DNA double helix structure. This year is the 70th anniversary. It was on this day, in 1953, that Watson and Crick, with the precious contribution of Rosalind Franklin, described the structure of DNA and its double helix.

Thanks to this discovery, GENinCode tests now provide information about inherited conditions, disease diagnosis and improved risk assessment in cardiovascular disease.

Our tests are designed to help physicians make improved clinical decisions. With comprehensive genetic risk assessment, we are able to stratify patients at most risk and identify personalised treatment to prevent cardiovascular disease.

The GENinCode preventative cardiology approach is now being applied to healthcare systems across the US, UK and Europe to advance preventative care, deliver efficient resource management and improve outcomes.

08/04/2024

The future is now! We are delighted with the American Journal of Preventive Cardiology publication representing the first major clinical publication showing the clinical utility of CARDIO InCode-Score to identify individuals at high genetic risk of coronary heart disease, the leading cause of death globally. Read more…

Groundbreaking research by Kaiser Permanente paves the way for a personalised, predictive approach to combating coronary heart disease, potentially saving

07/11/2023

GENinCode is delighted to announce their support for the NHS Understanding Genomics Event being held on Wednesday 8th November at 15 Hatfields, London. We look forward to attending the event and meeting with our friends and colleagues.

Please contact us at info@genincode.com if you would like to arrange a one-to-one meeting time or use the following link: https://www.convenzis.co.uk/genincode

29/09/2023

In 2020, an estimated 523 million people had some form of cardiovascular disease (CVD), with approximately 19 million deaths attributable to CVD; this represents approximately 32% of all global deaths and is an absolute increase of 18.7% from 2010

Risk factors such as age, smoking, eating habits account for approx 50% of the likelihood of developing CVD with the remaining 50% risk related to an individuals inherited genetics.

By understanding our genetics we can help reduce the risk of CVD.

World Heart Day raises awareness of the worlds biggest killer and how we can prevent and treat cardiovascular disease.

Read more:

www.genincode.com

24/05/2023

GENinCode announces its collaboration with the University Clinic Dresden, Germany for the implementation of LIPID inCode® to improve genetic diagnosis of hypercholesterolemia (high levels of cholesterol) and inherited familial hypercholesterolemia (FH) to prevent cardiovascular disease.

60% of the German population suffer from high levels of cholesterol and it is estimated that over a quarter of a million of these cases relate to FH. The University Clinic Dresden lipid centre constitutes one of the largest academic lipid apheresis centres globally. Approximately 6 million people in Germany live with heart and circulatory diseases, which accounts for 25% of all deaths annually.

LIPID inCode® detection of patients with inherited hypercholesterolemia supports improved treatment and prevention of cardiovascular disease.

🧬https://genincode.com/announcement-of-collaboration-with-university-clinic-dresden-germany-for-the-implementation-of-lipid-incode-testing/

08/05/2023

The NHS expansion of LIPID inCode® testing for Familial Hypercholesterolemia (FH) enables the identification, earlier diagnosis and treatment of patients at high genetic risk of a heart attack, a vitally important step to help reduce cardiovascular disease mortality in the UK. Earlier detection of patients with FH supports better treatment and preventative care to avoid a heart attack.
The acceleration of LIPID inCode® testing will support the delivery of the NHS 10 Year Plan to identify at least 25% of those individuals suffering with FH by 2024 as part of the NHS genomics programme. The NHS 10 Year Plan for FH is at the forefront of cardiovascular clinical improvements to reduce CVD mortality in the UK.

NHS earmarks budget to expand GENinCode’s LIPID inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease, announces the expansion of its collaboration with the Academic Health Scienc...

25/04/2023

World DNA Day is an annual, global celebration of the discovery of the DNA double helix structure. This year is the 70th anniversary. It was on this day, in 1953, that Watson and Crick, with the precious contribution of Rosalind Franklin, described the structure of DNA and its double helix.

Thanks to this discovery, GENinCode tests now provide information about inherited conditions, disease diagnosis and improved risk assessment in cardiovascular disease.

Our tests are designed to help physicians make improved clinical decisions. With comprehensive genetic risk assessment we are able to stratify patients at most risk and identify personalised treatment to prevent cardiovascular disease.

The GENinCode preventative cardiology approach is now being applied to healthcare systems across the US, UK and Europe to advance preventative care, deliver efficient resource management and improve outcomes.

12/04/2023

➡️ https://www.genincode.com/us-cpt-pla-code-granted-for-cardio-incode-score-cic-score-_-cpt-pla-code-is-key-component-for-reimbursement-from-private-medical-insurance-and-medicare/

19/01/2023

We are delighted to announce the collaboration with the Extremadura Health Service region of Spain (SES) for the implementation of the CARDIO inCode-SCORE® (CIC-SCORE) genetic test to improve the prevention of cardiovascular diseases in Primary Care.

Learn more about this here: We are delighted to announce the collaboration with the Extremadura Health Service region of Spain (SES) for the implementation of the CARDIO inCode-SCORE® (CIC-SCORE) genetic test to improve the prevention of cardiovascular diseases in Primary Care.



Learn more about this here:

First pilot test in Spanish Primary Care, resulting from an agreement between the Predictive Genetics company GENinCode and the Extremadura Health Service, to improve cardiovascular disease (CVD) prevention. CARDIO inCode® is a world leading Personalised Medicine test, with significant scientific a...

10/01/2023

Learn more about this here:

https://www.genincode.com/approval-of-california-state-license-and-clia-certification-opens-us-market-2/

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”), announces California state licensing approval and CLIA certification of its Irvine laboratory in California, enabling the provision of its products for the risk ass...

16/11/2022

We are delighted to announce the BMJ publication and positive results of the ALDO study. This study was conducted in women with a BRCA mutation who defer preventative surgery. The ROCA Test identified cancer earlier and showed a cost saving benefit to NHS.

Learn more about this here:

https://www.therocatest.co.uk/

13/10/2022

is an initiative to raise awareness of the prevalence of blood clots and actions individuals can take to mitigate the risk of this condition.
 
Importantly, inherited genetics play a significant role in determining the likelihood of suffering from thrombosis.
 
Please help raise awareness by sharing this post.